Skip to main content

NovoCure Ltd (NVCR) Stock Forecast 2025 - AI Price Prediction & Analysis


NovoCure Ltd (NVCR) AI Stock Price Forecast & Investment Analysis

NovoCure Ltd Stock Price Chart and Technical Analysis

Loading NovoCure Ltd interactive price chart and technical analysis...

NovoCure Ltd (NVCR) - Comprehensive Stock Analysis & Investment Research

Deep dive into NovoCure Ltd's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about NovoCure Ltd, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For NovoCure Ltd: NovoCure Ltd operates in the Industrial Applications and Services sector, making it an emerging small-cap investment.

NovoCure Ltd (Stock Symbol: NVCR) is a leading company in the Industrial Applications and Services sector , specifically operating within the Surgical & Medical Instruments & Apparatus industry.

The organization employs approximately 1224 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing NovoCure Ltd's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For NovoCure Ltd: With $630M in annual revenue and -25.9% net margin, the company demonstrates developing profitability.

Annual Revenue: $630 million generating a -25.9% net profit margin .

Market Capitalization: $1419 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -14.6% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for NovoCure Ltd stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For NovoCure Ltd: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for NovoCure Ltd stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: NovoCure Ltd's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For NovoCure Ltd: Strong free cash flow generation demonstrates developing operational efficiency.

NovoCure Ltd strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company demonstrates robust operational efficiency through strong free cash flow generation of $36 million annually, complemented by impressive 272.5% year-over-year cash flow growth.

The company maintains a healthy 76.4% gross margin, indicating strong pricing power and operational efficiency.

NovoCure Ltd (NVCR) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for NovoCure Ltd stock analysis.

Loading NovoCure Ltd comprehensive fundamental analysis and insider trading data...

Deep dive into NovoCure Ltd's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if NovoCure Ltd stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For NovoCure Ltd: With a P/E ratio of -20.83, the market sees the stock as potentially undervalued.

P/E Ratio -20.83x
P/B Ratio 4.06x
Market Cap $1419M
EPS $-1.56
Book Value/Share $3.13
Revenue/Share $5.64
FCF/Share $0.38
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently NovoCure Ltd converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For NovoCure Ltd: An ROE of -14.6% indicates room for improvement in shareholder value creation.

ROE -14.6%
ROA -5.3%
ROIC -6.0%
Gross Margin 76.4%
Operating Margin -27.5%
Net Margin -25.9%
EBT Margin -9.6%
Tax Rate 217.3%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess NovoCure Ltd's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For NovoCure Ltd: A current ratio of 8.46 indicates strong liquidity.

Current Ratio 8.46x
Quick Ratio 8.22x
D/E Ratio 1.33x
Financial Leverage 2.64x
Interest Coverage -14.1x
Working Capital $886M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal NovoCure Ltd's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For NovoCure Ltd: Free cash flow of $36M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $61M
Free Cash Flow $36M
Capital Spending $-25M
OCF Growth YoY 272.5%
FCF Growth YoY 421.7%
FCF/Sales 6.7%
CapEx/Sales 4.7%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively NovoCure Ltd uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For NovoCure Ltd: An asset turnover of 0.49x suggests room for improvement in asset utilization.

Asset Turnover 0.49x
Receivables Turnover 5.6x
Inventory Turnover 4.1x
Fixed Assets Turnover 10.8x
Days Sales Outstanding 66 days
Days Inventory 90 days
Payables Period 191 days
Cash Conversion Cycle -36 days
Understanding Financial Statement Data

What these metrics mean: Key figures from NovoCure Ltd's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For NovoCure Ltd: With annual revenue of $630M, NovoCure Ltd demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $630M
R&D Expense $213M
SG&A Expense $50M
Cost of Goods Sold $-96M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 94%
Cash & Short-term Investments 81%
Total Liabilities 62%
Accounts Receivable 10%
Inventory 3%
Dividend & Shareholder Information
Shares Outstanding 112M
Growth Metrics (YoY)
EPS Growth -6.3%

Latest NovoCure Ltd Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting NovoCure Ltd (NVCR) stock price and investment outlook.

, source: MarketWatch

Novocure Ltd. NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called ...

, source: Benzinga.com

Novocure Ltd NVCR shares are falling after the company's phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with ...

, source: Yahoo Finance

Earnings call NovoCure reported Q1 2025 revenue of $155M, up 12% YoY, with 11% growth in active patients. Early uptake in non-small cell lung cancer (NSCLC) is encouraging, with 92 prescriptions and ...

, source: Yahoo Finance

Earnings call Q2 2025 revenue rose 6% YoY to $159M, fueled by 7% GBM patient growth and $2.4M in early OptuneLua sales. Gross margin declined to 74% due to launch costs. PMA filings for pancreatic and ...

NovoCure Ltd Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of NovoCure Ltd against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM Unlock Forecast - 30 Days FREE Trial $26M x 3.0x
ALUR Unlock Forecast - 30 Days FREE Trial $17M -0.4x -0.3x
ANGO Unlock Forecast - 30 Days FREE Trial $442M -1.4x 2.4x
ANIK Unlock Forecast - 30 Days FREE Trial $128M -4.3x 0.9x
AORT Unlock Forecast - 30 Days FREE Trial $1805M -198.2x 4.3x
APYX Unlock Forecast - 30 Days FREE Trial $89M -3.5x 12.3x
ATEC Unlock Forecast - 30 Days FREE Trial $2274M -7.4x 95.7x
ATRC Unlock Forecast - 30 Days FREE Trial $1810M -39.6x 3.9x
AVHHL Unlock Forecast - 30 Days FREE Trial $27M x x
BAX Unlock Forecast - 30 Days FREE Trial $12132M -94.9x 1.7x
BBNX Unlock Forecast - 30 Days FREE Trial $976M x 3.2x
BDX Unlock Forecast - 30 Days FREE Trial $53749M 33.9x 2.1x
BEAT Unlock Forecast - 30 Days FREE Trial $57M -5.7x 13.8x
BJDX Unlock Forecast - 30 Days FREE Trial $2M -0.5x 0.4x
BSX Unlock Forecast - 30 Days FREE Trial $144402M 57.6x 6.4x
BVS Unlock Forecast - 30 Days FREE Trial $595M -18.3x 3.7x
CARL Unlock Forecast - 30 Days FREE Trial $-20M x x
CLPT Unlock Forecast - 30 Days FREE Trial $318M -23.5x 16.1x
CODX Unlock Forecast - 30 Days FREE Trial $16M -0.7x 0.4x
CVRX Unlock Forecast - 30 Days FREE Trial $187M -5.5x 3.2x
DCTH Unlock Forecast - 30 Days FREE Trial $460M 206.2x 4.4x
DRTS Unlock Forecast - 30 Days FREE Trial $348M x 4.0x
DXCM Unlock Forecast - 30 Days FREE Trial $30903M 54.1x 12.0x
EBRCZ Unlock Forecast - 30 Days FREE Trial $337M x 6.8x
FEMY Unlock Forecast - 30 Days FREE Trial $11M -1.4x 7.6x
FOFA Unlock Forecast - 30 Days FREE Trial $8M x 14.6x
GIPL Unlock Forecast - 30 Days FREE Trial $5M x 25.6x
GKOS Unlock Forecast - 30 Days FREE Trial $4914M -46.3x 6.4x
GMED Unlock Forecast - 30 Days FREE Trial $7839M 22.0x 1.8x
HRGN Unlock Forecast - 30 Days FREE Trial $31M x 40.6x
IART Unlock Forecast - 30 Days FREE Trial $1099M 200.2x 1.1x
ICCM Unlock Forecast - 30 Days FREE Trial $62M x 21.3x
ICUI Unlock Forecast - 30 Days FREE Trial $3248M -49.8x 1.6x
IDXG Unlock Forecast - 30 Days FREE Trial $23M 4.4x -0.9x
IINN Unlock Forecast - 30 Days FREE Trial $30M x 7.0x
IINNW Unlock Forecast - 30 Days FREE Trial $8M x 1.9x
INBS Unlock Forecast - 30 Days FREE Trial $9M -0.3x 3.0x
INFU Unlock Forecast - 30 Days FREE Trial $213M 42.0x 3.9x
INSP Unlock Forecast - 30 Days FREE Trial $2365M 44.5x 3.5x
IRMD Unlock Forecast - 30 Days FREE Trial $905M 43.8x 9.6x
IRTC Unlock Forecast - 30 Days FREE Trial $5663M -20.2x 54.6x
KIDS Unlock Forecast - 30 Days FREE Trial $448M -20.7x 1.3x
KMTS Unlock Forecast - 30 Days FREE Trial $1350M x x
KRMD Unlock Forecast - 30 Days FREE Trial $192M -19.8x 11.6x
LNSR Unlock Forecast - 30 Days FREE Trial $59M -6.7x -7.0x
LUCD Unlock Forecast - 30 Days FREE Trial $111M -0.6x 14.1x
LUNG Unlock Forecast - 30 Days FREE Trial $69M -4.3x 1.0x
MCAG Unlock Forecast - 30 Days FREE Trial $22M x -9.6x
MCAGU Unlock Forecast - 30 Days FREE Trial $21M x -9.9x
MDNC Unlock Forecast - 30 Days FREE Trial $59M 26.8x 13.4x
MDXG Unlock Forecast - 30 Days FREE Trial $1050M 32.6x 4.9x
MGRM Unlock Forecast - 30 Days FREE Trial $211M -10.7x 24.5x
MHUA Unlock Forecast - 30 Days FREE Trial $13M x 0.1x
MMM Unlock Forecast - 30 Days FREE Trial $85312M 21.7x 19.9x
MMSI Unlock Forecast - 30 Days FREE Trial $5093M 42.8x 3.4x
NEPH Unlock Forecast - 30 Days FREE Trial $39M -20.3x 2.0x
NMTC Unlock Forecast - 30 Days FREE Trial $46M -1.7x 5.7x
NPCE Unlock Forecast - 30 Days FREE Trial $328M -10.4x 16.9x
NSPR Unlock Forecast - 30 Days FREE Trial $124M -4.3x 6.1x
NVCR Unlock Forecast - 30 Days FREE Trial $1419M -20.8x 4.1x
NXGL Unlock Forecast - 30 Days FREE Trial $22M -6.8x 4.6x
OBIO Unlock Forecast - 30 Days FREE Trial $118M -3.4x 2.0x
OFIX Unlock Forecast - 30 Days FREE Trial $581M -5.8x 1.3x
OSRH Unlock Forecast - 30 Days FREE Trial $25M x 0.3x
OSUR Unlock Forecast - 30 Days FREE Trial $253M 17.1x 0.7x
PAVM Unlock Forecast - 30 Days FREE Trial $20M 0.3x 0.5x
PDEX Unlock Forecast - 30 Days FREE Trial $115M 12.9x 3.2x
PEN Unlock Forecast - 30 Days FREE Trial $10023M 67.9x 7.8x
PLRZ Unlock Forecast - 30 Days FREE Trial $7M x 0.4x
PMI Unlock Forecast - 30 Days FREE Trial $44M x x
PODD Unlock Forecast - 30 Days FREE Trial $23559M 99.8x 16.1x
PRCT Unlock Forecast - 30 Days FREE Trial $2075M -45.4x 5.4x
PROF Unlock Forecast - 30 Days FREE Trial $130M x 3.3x
PYPD Unlock Forecast - 30 Days FREE Trial $54M x 2.6x
RCEL Unlock Forecast - 30 Days FREE Trial $145M -5.0x -29.9x
RDGL Unlock Forecast - 30 Days FREE Trial $42M x 15.8x
RMD Unlock Forecast - 30 Days FREE Trial $40361M 28.8x 6.8x
RSMDF Unlock Forecast - 30 Days FREE Trial $3663M 2.6x 0.6x
RTGN Unlock Forecast - 30 Days FREE Trial $66M x x
RVP Unlock Forecast - 30 Days FREE Trial $25M -0.9x 0.3x
SGHT Unlock Forecast - 30 Days FREE Trial $187M -3.7x 2.7x
SIBN Unlock Forecast - 30 Days FREE Trial $628M -14.3x 3.7x
SKIN Unlock Forecast - 30 Days FREE Trial $321M -1.8x 4.3x
SNOA Unlock Forecast - 30 Days FREE Trial $7M -5.6x 1.7x
SNWV Unlock Forecast - 30 Days FREE Trial $299M x -19.4x
SOLV Unlock Forecast - 30 Days FREE Trial $13015M 34.3x 3.6x
SRTS Unlock Forecast - 30 Days FREE Trial $51M 31.6x 1.0x
SSKN Unlock Forecast - 30 Days FREE Trial $7M -8.0x 21.3x
STIM Unlock Forecast - 30 Days FREE Trial $213M -1.0x 7.9x
STME Unlock Forecast - 30 Days FREE Trial $12M x x
STSS Unlock Forecast - 30 Days FREE Trial $8M -2.5x 0.6x
SYK Unlock Forecast - 30 Days FREE Trial $140684M 42.0x 12.0x
TCMD Unlock Forecast - 30 Days FREE Trial $333M 22.0x 1.7x
TELA Unlock Forecast - 30 Days FREE Trial $73M -1.8x 8.0x
TFX Unlock Forecast - 30 Days FREE Trial $5676M 29.6x 1.3x
TNDM Unlock Forecast - 30 Days FREE Trial $849M -17.1x 6.4x
TNON Unlock Forecast - 30 Days FREE Trial $10M -0.3x 1.4x
USAQ Unlock Forecast - 30 Days FREE Trial $2M x x
UTMD Unlock Forecast - 30 Days FREE Trial $204M 16.2x 1.7x
VERO Unlock Forecast - 30 Days FREE Trial $5M 0.0x 2.2x
WST Unlock Forecast - 30 Days FREE Trial $18563M 38.1x 6.3x
XTNT Unlock Forecast - 30 Days FREE Trial $96M -478.8x 2.0x

Frequently Asked Questions - NovoCure Ltd Stock Forecast

How accurate are NovoCure Ltd stock predictions?

Our AI model demonstrates 65% historical accuracy for NVCR predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence NovoCure Ltd stock price forecasts?

Our analysis considers NovoCure Ltd's financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is NovoCure Ltd a good investment in 2025?

Based on our AI analysis, NovoCure Ltd shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are NovoCure Ltd forecasts updated?

NovoCure Ltd stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced NovoCure Ltd Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for NovoCure Ltd stock.

My Portfolio

Investment Dashboard

Loading your portfolio...